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CVD is the most common cause of death in people over 65 years. This review considers the
latest evidence for a potential protective effect of C1 donors (folate and the metabolically
related B-vitamins) in CVD. Such an effect may or may not be mediated via the role of
these nutrients in maintaining plasma homocysteine concentrations within a desirable range.
Despite predictions from epidemiological studies that lowering plasma homocysteine would
reduce cardiovascular risk, several secondary prevention trials in at-risk patients published
since 2004 have failed to demonstrate a benefit of homocysteine-lowering therapy with
B-vitamins on CVD events generally. All these trials were performed in CVD patients with
advanced disease; thus current evidence suggests that intervention with high-dose folic acid is
of no benefit in preventing another event, at least in the case of heart disease. The evidence at
this time, however, is stronger for stroke, with meta-analyses of randomised trials showing that
folic acid reduces the risk of stroke, particularly in people with no history of stroke. Genetic
studies provide convincing evidence to support a causal relationship between sub-optimal
B-vitamin status and CVD. People homozygous for the common C677T variant in the gene
encoding the folate-metabolising enzyme, methylenetetrahydrofolate reductase (MTHFR),
typically have a 14–21% higher risk of CVD. Apart from folate, riboflavin is required as a
co-factor for MTHFR. New evidence shows that riboflavin intervention results in marked
lowering of blood pressure, specifically in patients with the MTHFR 677TT genotype.
This novel gene–nutrient interaction may provide insights as to the mechanism that links C1
metabolism with CVD outcomes.
Cardiovascular risk: Homocysteine: MTHFR C677T polymorphism: Folate and folic acid:
Riboflavin
The B-vitamins folate, vitamins B12 and B6 and riboflavin
are the source of coenzymes which participate in C1 meta-
bolism. This metabolic process involves the transfer and
utilisation of C1 units for DNA and RNA biosynthesis,
methylation reactions and the metabolism of amino acids
including methionine. Homocysteine is a precursor of
methionine synthesis, in turn required for the generation of
the universal methyl donor S-adenosyl methionine. Normal
homocysteine metabolism requires an adequate supply of
up to four B-vitamins (Fig. 1). When the status of folate and
related B-vitamins is sub-optimal, plasma homocysteine
concentration is invariably found to be elevated, while
supplementation with the relevant B-vitamins can lower
homocysteine, in healthy and diseased populations, by
about 25% with folic acid(1) and to a generally lesser extent
with vitamins B12
(2) and B6
(3) and riboflavin(4). Thus,
the measurement of plasma homocysteine concentration
provides a reliable functional marker of B-vitamin status.
Abbreviations: MTHFR, methylenetetrahydrofolate reductase; RCT, randomised controlled trials.
*Corresponding author: Professor Helene McNulty, fax + 44 28-70124965, email h.mcnulty@ulster.ac.uk
Proceedings of the Nutrition Society (2012), 71, 213–221 doi:10.1017/S0029665111003387
g The Authors 2011 First published online 12 December 2011
https://doi.org/10.1017/S0029665111003387
Downloaded from https:/www.cambridge.org/core. University of Ulster, on 07 Mar 2017 at 21:11:49, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
Homocysteine as a risk factor for CVD: Lines of
evidence
Homocysteine has been considered for many years to be a
risk factor for CVD when its concentration in plasma is
elevated but this is somewhat controversial. Apart from the
responsiveness of plasma homocysteine to the lowering
effects of B-vitamin intervention(1–4), folate and related
B-vitamins may have roles in CVD which are independent
of their effects on homocysteine. Thus, while the literature
in this area focuses predominantly on homocysteine per se
as the cardiovascular risk factor, it is possible that elevated
plasma homocysteine is merely a marker of sub-optimal
B-vitamin status rather than being causatively linked with
CVD. In any case, the value of plasma homocysteine as a
measurement lies in the fact that its concentration has been
investigated in numerous human studies of CVD and such
studies may not necessarily have also included biomarker
measurements of the various B-vitamins that act as C1
donors. It is beyond the scope of this review to separate
homocysteine-lowering from enhanced folate status as the
relevant physiological event of potential benefit and one
that responds to intervention. Instead, in describing the
evidence, the appropriate phraseology is used to indicate
that any potential beneficial effect of homocysteine-
lowering may well relate to enhanced B-vitamin status.
Evidence from observational studies
Clinical studies of patients with CVD published over the
past 20 years provide much evidence to link low folate
status and/or elevated plasma homocysteine with an
increased risk of CVD. The data from numerous such
studies, both retrospective and prospective, were used to
generate two important meta-analyses, both published in
2002(6,7). They predicted that lowering homocysteine by
3mmol/l (or by about 25% based on typical homocysteine
concentrations of 12mmol/l) would reduce the risk of heart
disease by 11–16% and stroke by 19–24%(6,7). Apart from
clinical studies, population data from North America
showed an improvement in stroke mortality corresponding
to the timing of the introduction of mandatory food
fortification with folic acid in 1996–98 and no similar
improvement over the same time period in the UK where
no such fortification policy was put in place(8). Thus, the
temporal decline in stroke-related mortality in the US and
Canada which coincided with the introduction of folic acid
fortification was consistent with a beneficial effect of folic
acid or homocysteine-lowering on CVD(8). Randomised
trials, however, were required in order to prove a cause-
and-effect relationship.
Evidence from randomised controlled trials
Since 2004, the results of a number of much-awaited
secondary prevention trials in at-risk patients began to
appear in high-profile medical journals(9–15). All these
failed to demonstrate a benefit of homocysteine-lowering
therapy on CVD events generally (Table 1). Some argued
that these trials lacked sufficient statistical power to
detect a beneficial effect, given that the magnitude of
the association between homocysteine and CVD risk on
Fig. 1. Pathways for the metabolism of homocysteine. MTHFR, methylenetetrahydrofolate reductase;
DMG, dimethylglycine. Reproduced from Strain et al.(5).
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Table 1. Randomised controlled trials (RCT) of homocysteine-lowering and CVD events: secondary prevention
Authors/Trial/Country Population studied Treatment (mg/d) Main result/Conclusion
Toole et al.(9)/Vitamin Intervention for
Stroke Prevention (VISP) trial/USA,
Canada, Scotland
Patients (n 3680) with non-disabling
cerebral infarction
2.5 FA, 0.4 B12, 25 B6 or 0.02 FA,
0.006 B12, 0.2 B6 for 2 years
RR 1.0 (95% CI 0.8, 1.3) for ischaemic stroke
RR 1.0 (95% CI 0.8, 1.1) for any stroke,
CHD event or death
No effect on vascular outcomes
Lonn et al.(10)/Heart Outcomes Prevention,
Evaluation 2 (HOPE 2) study/Canada,
USA, Brazil, Western Europe, Slovakia
Patients (n 5522) with vascular
disease or diabetes
2.5 FA, 50 B6, 1 B12 or placebo
for 5 years
RR 0.95 (95% CI 0.84, 1.07)
No reduction in the risk of death
from cardiovascular causes
Bønaa et al.(11)/Norwegian Vitamin
(NORVIT) trial/Norway
Acute MI patients (n 3749) 0.8 FA, 0.4 B12, 40 B6 or 0.8 FA, 0.4
B12 or 40 B6 or placebo for 40 months
RR 1.22 (95% CI 1.00, 1.50) for FA, B12, B6
RR 1.08 (95% CI 0.93, 1.25) for FA, B12
RR 1.14 (95% CI 0.98, 1.32) for B6
No lowering in the risk of recurrent MI,
stroke and sudden death attributed to CAD
Ebbing et al.(12)/Western Norway
B-vitamin Intervention Trial
(WENBIT)/Norway
Patients (n 3096) undergoing
coronary angiography
0.8 FA, 0.4 B12, 40 B6 or 0.8 FA, 0.4
B12 or 40 B6 or placebo for 38 months
HR 1.09 (0.9–1.32) for FA, B12
HR 0.90 (0.74–1.09) for B6
No effect of treatment on total mortality
or cardiovascular events (non-fatal
acute MI, acute hospitalisation for
unstable angina pectoris and non-fatal
thromboembolic stroke)
Albert et al.(13)/Women’s Antioxidant
and Folic Acid Cardiovascular Study
(WAFACS)/USA
Women (n 5442) with a history
of CVD or three or more
coronary risk factors
2.5 FA, 1 B12, 50 B6 or placebo
for 7.3 years
RR 1.03 (95% CI 0.90, 1.19)
No reduction in MI, stroke, coronary
revascularisation or CVD mortality
SEARCH Collaborative Group 2010(14)/Study
of the Effectiveness of Additional Reductions
in Cholesterol and Homocysteine
(SEARCH)/UK
MI patients (n 12 064) 2 FA, 1 B12 or placebo for 6.7 years RR 1.04 (95% CI 0.97, 1.12)
No beneficial effects on coronary death,
MI, coronary revascularisation, fatal or
non-fatal stroke or non-coronary
revascularisation
The VITATOPS Trial Study Group
2010(15)/VITAmins TO Prevent Stroke
(VITATOPS) trial/20 countries on five
continents
Patients (n 8164) with recent
stroke or TIA
2 FA, 0.5 B12, 25 B6 or placebo
for 3.4 years
RR 0.91 (95% CI 0.82, 1.00)
No significant reduction in incidence
of stroke, MI or vascular death
MI, myocardial infarction; CAD, coronary artery disease; TIA, transient ischaemic attack; RR, relative risk; HR, hazard ratio; FA, folic acid; B12, vitamin B12; B6, vitamin B6.
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re-evaluation of the epidemiological evidence was later
found to be more modest than originally estimated at the
time the trials were being designed(16). The relationship for
homocysteine and stroke, however, was always estimated
to be stronger than that for heart disease(6,7). In fact one of
the aforementioned trials, the HOPE 2 trial(10), had shown
a clear benefit of B-vitamin intervention in reducing the
risk of stroke, a result that for some reason was largely
overlooked in the original report. Instead, the positive
results of the trial in relation to stroke risk were separately
reported 3 years after the original trial findings(17), but
these later results were not as widely recognised as the
original report of the HOPE 2 trial. Of greater note,
a meta-analysis of randomised controlled trials (RCT)
showed that homocysteine-lowering by folic acid reduced
the risk of stroke in general by 18%, but with significantly
greater reductions observed (by 23–29%) in those trials
of longer treatment duration or with greater homocysteine-
lowering or in patients with no history of stroke
(Table 2)(18). Likewise, a more recent meta-analysis also
showed that the beneficial effect of folic acid on stroke risk
was to be found in trials longer than 3 years in duration,
with a homocysteine-lowering effect of 20% or greater and
in non-secondary prevention of stroke (Table 2)(19). In
addition the latter meta-analysis suggested for the first time
that folic acid intervention might be more beneficial in
men than in women; however, this finding requires further
verification as none of the trials evaluated had exclusively
investigated men or women. The evidence from these
meta-analyses of RCT, together with the aforementioned
North American population data suggesting a beneficial
effect of increased folate status (through mandatory for-
tification) in preventing stroke, means that the case for
enhanced folate and/or homocysteine-lowering in prevent-
ing CVD is stronger for stroke than for heart disease, and
perhaps strongest for the primary prevention of stroke.
Evidence from genetic studies
Other evidence for a causal relationship between low
folate status or elevated homocysteine and CVD comes
from genetic studies. The most important genetic determi-
nant of homocysteine in the general population is the
common C677T variant in the gene encoding the folate-
metabolising enzyme methylenetetrahydrofolate reductase
(MTHFR) required for the formation of 5-methyltetrahy-
drofolate which, in turn is required in the remethylation of
homocysteine to methionine. People who are homozygous
for this polymorphism (TT genotype), have reduced
MTHFR activity resulting in impaired folate metabolism
and higher homocysteine concentrations in vivo(20); a
phenotype that is found to be particularly marked in people
who also have low status of folate(21). The MTHFR 677 TT
genotype has a reported frequency of 10% worldwide,
ranging from 4 to 26% in Europe, 20% in Northern
China to as high as 32% in Mexico(22). Evidence from
various meta-analyses of genetic studies including data for
homocysteine concentrations and CVD events shows that
individuals with the MTHFR 677 TT genotype have a
significantly higher risk of CVD (by 14–21%) compared
with those without this polymorphism(7,23,24). The trend
towards increasing risk of disease shown among indivi-
duals with wild-type (CC), heterozygous (CT) and homo-
zygous mutant (TT) genotypes is consistent with the
increasing gradient in homocysteine concentrations typi-
cally found among the three genotypes(7,23), as would be
expected if there is a causal relationship between elevated
homocysteine and risk of disease. Analysis of the OR
among different countries, however, shows a large geo-
graphical variation in the extent of association between this
polymorphism and CVD risk. Meta-analyses, which have
examined this variation in relation to heart disease, show
that the excess risk is not significant in North American
Table 2. Randomised controlled trials (RCT) of homocysteine-lowering and risk of stroke: a meta-analysis
Wang et al.(18) Lee et al.(19)
(8 RCT; n 16 841) (13 RCT; n 39 005)
Relative risk (95% CI) P value Relative risk (95% CI) P value
Overall 0.82 (0.68, 1.00) 0.045 0.93 (0.85, 1.03) 0.16
Duration of intervention
<3 years 1.00 (0.83, 1.21) 0.95 1.03 (0.84, 1.27) NS
‡ 3 years 0.71 (0.57, 0.87) 0.001 0.87 (0.78, 0.98) 0.02
Homocysteine lowering
<20% 0.89 (0.55, 1.42) 0.62 1.02 (0.86, 1.22) NS
‡ 20% 0.77 (0.63, 0.94) 0.012 0.87 (0.77, 0.98) 0.02
History of stroke*
Yes 1.04 (0.84, 1.29) 0.71 1.04 (0.84, 1.29) NS
No 0.75 (0.62, 0.90) 0.002 0.89 (0.79, 0.99) 0.03
Gender effect
Predominantly women N/a N/a 1.11 (0.83, 1.49) NS
Predominantly men N/a N/a 0.84 (0.74, 0.94) 0.003
N/a, not applicable.
*Referred to as secondary and non-secondary stroke prevention in Lee et al. meta-analysis(19).
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populations, while the TT genotype carries a significantly
increased (but variable) risk of CHD elsewhere in the
world(23,24). The largest and most recent investigation in
this area, a collaboration of genetic studies consisting of
data on almost 60 000 individuals including 20 885 stroke
events, reported that the association between the MTHFR
677TT genotype and stroke was evident only in regions of
low folate, whereas in regions with folic acid fortification
policies the effect of MTHFR genotype was null(25). Thus,
the general conclusion emerging from genetic studies to
date is one of effect modification by population dietary
folate on the association between this polymorphism and
CVD risk.
The mechanism whereby this genetic variant is linked
with an increased risk of CVD is not generally dealt with
in these reports but is generally assumed to relate to the
phenotype of elevated plasma homocysteine in some
way(23–25). Riboflavin, the co-factor for MTHFR, has been
largely overlooked as a potential modulator of the pheno-
type, or indeed the cardiovascular risk, associated with the
MTHFR C677T polymorphism. This omission is despite
evidence that intervention with riboflavin lowers plasma
homocysteine specifically in individuals with the MTHFR
677TT genotype, and unlike folate and vitamin B12, ribo-
flavin does not have a homocysteine-lowering effect in the
other MTHFR genotype groups(4). This finding suggests
that riboflavin intervention can in some way stabilise
MTHFR activity in individuals with the MTHFR 677TT
genotype and restore enzyme activity to levels found in
those without this genotype.
C1 metabolism and hypertension, a major CVD
risk factor
Hypertension (i.e. a blood pressure of 140/90mmHg or
greater) is estimated to carry an almost threefold greater
risk of developing CVD(26), while treating hypertension
substantially reduces cardiovascular events, and stroke in
particular(27). As reviewed by us recently, plasma homo-
cysteine concentrations are found to be associated with
blood pressure in most (though not all) large cohort stu-
dies(28). Most published studies in this area, however, have
not considered the role of the MTHFR C677T polymorph-
ism, but emerging evidence shows an important association
between this common genetic factor and hypertension(28).
Moreover, new evidence has identified that riboflavin can
play an important role in determining blood pressure spe-
cifically in CVD patients with the MTHFR 677TT geno-
type(29). Intervention with riboflavin (at dietary levels,
1.6mg/d) was found to result in marked lowering of blood
pressure (from 144/87 to 131/80mmHg) in CVD patients
with the TT genotype and no response in the other MTHFR
genotype groups(29). These findings could have important
implications for the prevention and management of
hypertension among the 10% of individuals worldwide(22)
who carry this genotype.
Presumably the effect of riboflavin in individuals with
the MTHFR 677TT genotype is to stabilise the variant
enzyme that is known from molecular studies to become
inactive as a result of having an increased propensity to
dissociate from its FAD co-factor(30). The mechanism,
however, which links riboflavin with blood pressure in this
genotype group is as yet unknown. The potent vasodilator
NO may possibly be implicated. Vascular tissue con-
centrations of 5-methyltetrahydrofolate (rarely measured in
human studies) were recently found to be lower in patients
with the MTHFR 677TT genotype and were associated
with NO regulation and endothelial function in these
patients(31). By stabilising the variant MTHFR enzyme,
it is possible that riboflavin supplementation could restore
5-methyltetrahydrofolate concentrations in vascular tissues,
improve NO bioavailability and in turn lower blood pres-
sure specifically in patients with the TT genotype. Clearly,
further investigation to determine the precise mechanism is
required, but the elevated homocysteine phenotype typi-
cally associated with this polymorphism is unlikely to be
directly implicated. Despite the significant associations that
are found between plasma homocysteine and blood pres-
sure in several observational studies, intervention studies to
lower homocysteine have shown little or no corresponding
blood pressure response(28), suggesting that there is no
causative link between elevated homocysteine concentra-
tions per se and hypertension.
Whatever the mechanism, this novel genotype-specific
effect of riboflavin on blood pressure may, if confirmed,
also help to explain the aforementioned inconsistencies
in the evidence as to the role of the MTHFR C677T
polymorphism in CVD generally(23–25). The policy of
population-wide riboflavin fortification of food, which has
existed for over 50 years in North America, would ensure
higher and generally less variable intakes of riboflavin
compared with elsewhere. The higher riboflavin status
could in turn be predicted to neutralise any effect of the
variant MTHFR enzyme. The reported differences among
countries as to whether this polymorphism represents an
increased risk of CVD may thus relate, not only to differ-
ences in the prevailing folate status as commonly sug-
gested(23–25) but also to the modulating effect of riboflavin.
Based on the genotype-specific effect of riboflavin on
blood pressure recently shown(29), it could be predicted
that individuals with the TT genotype who also have low
riboflavin status would have an excess risk of CVD,
whereas TT homozygotes with optimal riboflavin status
may not show the expected risk. No study, however, has
addressed this possibility.
Potential for prevention of stroke through
optimisation of B-vitamin status
Folate
Taken together, the evidence showing a decline in stroke-
related mortality in North America corresponding to the
introduction of mandatory folic acid-fortification(8), along
with the evidence from RCT showing beneficial effects
of folic acid in people with no previous history of
stroke(18,19), suggest that folic acid may have an important
role to play in the primary prevention of stroke. Thus,
although aimed at preventing neural-tube defects, folic
acid fortification on a population-wide basis may also
prevent stroke. Randomised trials that have failed to show
B-vitamins and CVD 217
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beneficial effects of folic acid on stroke have in general
been conducted in countries with a high prevailing folate
status(25). Thus, it is unlikely that further increases in folate
intake will be effective in a population whose folate status
is generally optimal. However, while overt folate defi-
ciency (i.e. megaloblastic anaemia) is relatively rare in the
absence of an underlying clinical cause, many otherwise
healthy populations have inadequate folate intakes when
considered from the perspective of achieving optimal sta-
tus rather than merely preventing deficiency of folate(32).
The poor stability and poor bioavailability of folate from
natural food sources compared with folic acid (the syn-
thetic vitamin form found in fortified foods and supple-
ments) means that achieving optimal folate status in a
population in the absence of a folic acid fortification policy
can be a major challenge(32). Thus, in populations with
limited or no access to fortified foods where consumers
are dependent on natural food folate sources to meet
their dietary intakes, folate status could be predicted to
be low(33). Intervention could be anticipated to have the
greatest benefit in reducing the risk of stroke in these
regions, and it is suggested that any future RCT of homo-
cysteine-lowering intervention for stroke prevention should
focus on such populations with low prevailing folate intake
and status(25).
Balanced against any potential benefits of folic acid in
preventing stroke, however, are concerns regarding poten-
tial adverse effects of long-term exposure to high folic acid
levels. Thus, mandatory folic acid fortification (aimed at
preventing neural-tube defects) remains very controversial,
despite the relative ineffectiveness of alternative strategies
to increase folate status through health promotion cam-
paigns(34). The major concern traditionally focused on the
potential risk that high folic acid intake might mask the
anaemia of vitamin B12 deficiency
(35), but more recently
the concern emerged that it could be associated with an
increased risk of cognitive dysfunction in older people with
low-vitamin B12 status
(36). Furthermore, despite consider-
able evidence that higher folate within the dietary range
plays a protective role against cancer at various sites(37–39),
other evidence suggests that exposure to high-dose folic
acid (>1mg/d) may promote colorectal tumorigenesis in
patients with pre-existing lesions(40) or even increase can-
cer risk generally(41,42). Thus, some remain concerned that
excessively high folic acid intakes could have a cancer-
promoting effect in segments of aging populations(43), and
policy-makers worldwide (including the UK government)
have delayed decisions to implement population-based
folic acid fortification policies similar to those introduced
in 1998 in North America.
Should emerging evidence prove the role of folic acid
in the primary prevention of stroke, then the public health
question of setting the appropriate folic acid dose to
achieve this beneficial effect in a population via food
fortification will need to be answered. A lower target dose
for beneficial effects will lower the risk of adverse effects
(whatever the estimated size of such risk) in any emerging
fortification policy. One recent trial from our Centre
addressed the issue of determining the lowest dose of
folic acid required to achieve a maximal lowering in
plasma homocysteine in heart disease patients and age- and
sex-matched controls(44). The results showed that a dose of
folic acid as low as 0.2mg/d can, if given chronically,
maximally lower homocysteine in patients and controls;
higher doses (0.4 and 0.8mg/d) resulted in no additional
lowering. By sampling participants at both 6 and 12 weeks,
in addition to the full intervention period of 26 weeks, the
trial also indicated that the majority of previous studies
used too short an intervention period to observe the full
extent of homocysteine-lowering in response to low folic
acid doses and thus concluded that the much higher folic
acid dose of 0.8mg/d was required(1). Thus, the potency
of folic acid at low doses given chronically (as in food
fortification) was previously underestimated, and these
findings indicate that long-term exposure to high-dose folic
acid through food fortification is unnecessary(44).
Vitamin B12
Vitamin B12, like folate, is required for the remethylation
of homocysteine to methionine (Fig. 1). Thus, achieving
optimal folate status alone may not lower homocysteine to
desirable concentrations (<10mmol/l)(45), and optimising
vitamin B12 may have benefits over and above the effect of
folate alone. A further 7% reduction in homocysteine
(additional to that with folic acid alone) can be achieved
with vitamin B12
(46). Any small additional decrease in
homocysteine could be predicted to confer a further benefit
in terms of cardiovascular risk given that the relationship
with homocysteine is a graded one(6,7). Although vitamin
B12 intakes are generally found to be more than adequate
in most healthy populations (often greatly exceeding
recommended values), the achievement of an optimal sta-
tus may be greatly hindered for many older people because
of the common problem of age-related food-bound vitamin
B12 malabsorption, estimated to affect up to 40% of
otherwise healthy older people(47,48). This problem arises
mainly from atrophic gastritis, a chronic inflammatory
condition, resulting in decreased gastric acid production
(hypochlorhydria), which diminishes vitamin B12 absorp-
tion because of the essential role of gastric acid in the
release of protein-bound vitamin B12 from food
(48). Unlike
the treatment required for the classical (but rare) vitamin
B12 deficiency sign of pernicious anaemia requiring vita-
min B12 injections for life, older adults with low vitamin
B12 status owing to food-bound malabsorption should be
able to absorb free (crystalline) vitamin B12 because it is
not bound to protein. In fact, on the basis of this assump-
tion, the Institute of Medicine in the USA recommends that
people aged 50 years and over consume most of their
vitamin B12 from crystalline vitamin B12 found in fortified
foods and supplements(49). No such recommendation exists
in the UK or any European country.
Riboflavin
Riboflavin is required as a co-factor for the folate-
metabolising enzyme MTHFR and therefore is needed to
generate 5-methyltetrahydrofolate which, in turn, acts in
the remethylation of homocysteine to methionine (Fig. 1),
but the potential role of riboflavin as a C1 donor is often
overlooked. The emerging evidence reviewed here that the
218 H. McNulty et al.
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higher blood pressure found in patients with a common
genetic variant in MTHFR is highly responsive to low-dose
riboflavin(29), raises the possibility that improving ribo-
flavin status will have an important role in preventing
hypertension and therefore in modulating the risk of
stroke specifically in the 10% of people worldwide (and
much higher in certain populations) with the relevant
genotype(22).
The Scientific Advisory Committee on Nutrition, how-
ever, has expressed concern about the high proportion of
the British adult population with apparently poor riboflavin
status as determined from national survey data using the
gold standard biomarker of status, erythrocyte glutathione
activation coefficient(50). In general, dietary intakes (pro-
vided in the diet predominantly through consuming milk
and dairy foods) were found to compare favourably with
recommended values; however, high proportions of young
women were found to have low intakes(50). Thus, it is
unclear at this time as to whether or not the large pro-
portion of the UK population with abnormal erythrocyte
glutathione activation coefficient values indicates a gen-
eralised problem of poor riboflavin status; this requires
further investigation.
Conclusions
Most of the RCT designed to show a causative relationship
between elevated plasma homocysteine and CVD provide
little evidence that giving folic acid or other B-vitamins to
CVD patients prevents another event. These interventions
were all secondary prevention trials conducted in patients
with advanced disease and, given the doses employed,
had little to do with nutrition. The same cannot be said
for primary prevention. Emerging nutrition policy should
consider nutrient requirements aimed at primary prevention
and it remains probable that there is a role for folic acid
and the metabolically related B-vitamins in the primary
prevention of stroke.
Although elevated plasma homocysteine per se is un-
likely to be causatively implicated in CVD, it is valuable
as a sensitive functional marker of sub-optimal B-vitamin
status. Correcting low folate and related B-vitamin status
(rather than lowering homocysteine) is probably the rele-
vant beneficial physiological event linked with CVD and
homocysteine-lowering may well be a bystander effect.
In any event, one needs to know the effective dose of
folic acid necessary to correct compromised folate status,
as evidenced by a return of the biomarker homocysteine
to normal plasma concentrations. In practice, however,
achieving an optimal status of the B-vitamins, folate,
vitamin B12 and riboflavin, on a population basis is chal-
lenging.
The difference in results of various meta-analyses in
relation to the MTHFR C677T polymorphism and stroke
risk is generally explained in the literature by the modify-
ing effect of prevailing folate status. Thus, high folate
is seen to overcome the detrimental effect of this poly-
morphism but the potential role of riboflavin in correcting
the associated impaired folate metabolism is generally
ignored. The emerging link between MTHFR genotype and
hypertension, however, may provide the basis of a
mechanism to explain how the common MTHFR C677T
polymorphism could result in increased CVD risk. The
elevated blood pressure associated with this polymorphism
is correctable by increasing riboflavin status; thus, stroke
risk could be predicted to also be responsive to riboflavin
intervention targeted at this genotype group but this con-
tention has not been addressed directly in any RCT to date.
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